Aurinia Pharmaceuticals (NASDAQ:AUPH) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Earnings and Valuation
This table compares Aurinia Pharmaceuticals and Nature's Sunshine Products' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Aurinia Pharmaceuticals | $320,000.00 | 4,918.81 | $-123,850,000.00 | ($0.89) | -13.88 |
| Nature's Sunshine Products | $362.21 million | 1.11 | $6.76 million | N/A | N/A |
Nature's Sunshine Products has higher revenue and earnings than Aurinia Pharmaceuticals.
Profitability
This table compares Aurinia Pharmaceuticals and Nature's Sunshine Products' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Aurinia Pharmaceuticals | -173,992.23% | -36.98% | -31.06% |
| Nature's Sunshine Products | 4.39% | 11.61% | 7.14% |
Institutional and Insider Ownership
51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.3% of Nature's Sunshine Products shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Aurinia Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Nature's Sunshine Products has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Aurinia Pharmaceuticals and Nature's Sunshine Products, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Aurinia Pharmaceuticals | 0 | 1 | 7 | 0 | 2.88 |
| Nature's Sunshine Products | 0 | 0 | 0 | 0 | N/A |
Aurinia Pharmaceuticals currently has a consensus price target of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' higher probable upside, equities analysts plainly believe Aurinia Pharmaceuticals is more favorable than Nature's Sunshine Products.
Summary
Nature's Sunshine Products beats Aurinia Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
